The recommended steps for treating postcardiotomy
|
|
- Evangeline Cobb
- 5 years ago
- Views:
Transcription
1 Feasibility Study of a Temporary Percutaneous Left Ventricular Assist Device in Cardiac Surgery Antonis A. Pitsis, MD, FETCS, Aikaterini N. Visouli, MD, Daniel Burkhoff, MD, PhD, Petros Dardas, MD, FESC, Nikolaos Mezilis, MD, FESC, Georgios Bougioukas, MD, and Gerasimos Filippatos, MD, FESC St. Luke s Hospital, Thessaloniki, Greece; Columbia University, New York, New York; Democritus University of Thrace, Alexandroupolis, and University of Athens, Athens, Greece Background. The aim of this study is to evaluate a percutaneous left ventricular assist device (Tandem Heart pvad; Cardiac Assist, Pittsburgh, Pennsylvania) in the postcardiotomy setting. Methods. Between August 2001 and August 2004, 11 high-risk male patients who had undergone heart failure surgery or surgical revascularization were supported by the TandemHeart postcardiotomy. The major indication for pvad insertion was failure to wean from cardiopulmonary bypass. Three different techniques were employed for cannulation: the closed percutaneous technique, the open transeptal technique with percutaneous cannulas insertion, and direct central cannulation. Results. The mean duration of support was 88 hours. The mean pump flow was 3.09 L/min. The weaning rate was 72.72%. Survival to discharge and at 1 and 4 years was 54.54%, 45.45%, and 36.36%, respectively. The main complication was pericardial bleeding, noted mainly in patients receiving antiplatelet treatment preoperatively. Conclusions. The TandemHeart appears to be safe for temporary support after cardiotomy. It is a versatile device allowing different techniques of insertion. Device application yielded high weaning rate and satisfactory early and long-term survival. (Ann Thorac Surg 2007;84:1993 9) 2007 by The Society of Thoracic Surgeons The recommended steps for treating postcardiotomy cardiogenic shock are early and aggressive medical treatment with inotropic agents, intra-aortic balloon pumping (IABP), and in patients refractory to these measures, mechanical circulatory support (MCS) [1, 2]. Weaning from cardiopulmonary bypass (CPB) with use of IABP is well established, although evidence for the efficacy of this approach is hard to produce [2, 3]. Cardiac output increases by 10% to 20%, mainly owing to reduced afterload and increased coronary perfusion, but IABP does not directly pump blood and does not significantly redistribute blood flow [3, 4], suggesting that the degree of hemodynamic compromise that can be treated with this device is relatively limited. Numerous devices, which generally require major surgery for insertion and removal, have been used with similar success for postcardiotomy MCS, none being inclusive of all the characteristics of an ideal device [4]. Devices for postcardiotomy support should allow easy implantation [4] and removal, and versatility of cannulation. Devices that allow peripheral cannulation include left ventricular assist devices (LVADs) with extracorporeal centrifugal pumps, intracorporeal miniaturized axial flow pumps, and the extracorporeal membrane oxygenation (ECMO) that provides cardiopulmonary support [4 6]. The TandemHeart percutaneous ventricular assist device (Tandem Heart pvad; Cardiac Assist, Pittsburgh, Accepted for publication June 15, Address correspondence to Dr Pitsis, St. Luke s Hospital, Panorama, Thessaloniki, 55236, Greece; apitsis@otenet.gr. Pennsylvania) allows percutaneous placement of inflow and outflow cannulas [7 9], with a technique resembling the one introduced by Dennis and used clinically by Edmunds and coworkers [10]. The TandemHeart includes a dual chambered, paracorporeal, continuousflow centrifugal pump. The upper pump housing provides inflow and outflow ports. The lower housing provides communication with the controller and an integral infusion line to provide local cooling and anticoagulation [8]. The device is Conformité Européenne marked. It has been most extensively used for short-term left ventricular (LV) support during high-risk percutaneous coronary interventions and for treatment of periinfarct cardiogenic shock [8, 9]. The goals of this feasibility study were to evaluate the safety and efficacy of the TandemHeart for postcardiotomy MCS. Patients and Methods Between August 2001 and August 2004, 14 patients (0.61% of cardiac cases) were supported by LVADs. Eleven patients were supported by the TandemHeart. We retrospectively reviewed the data of these 11 high-risk male patients. The Institutional Ethics Committee approved this study, and consent was obtained from the patients. Seven patients had chronic heart failure with severely dilated hearts due to ischemic cardiomyopathy or valvular heart disease. They mainly underwent heart failure surgery including surgical ventricular remodeling. Acute 2007 by The Society of Thoracic Surgeons /07/$32.00 Published by Elsevier Inc doi: /j.athoracsur
2 1994 PITSIS ET AL Ann Thorac Surg FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 2007;84: Table 1. Baseline Characteristics and Indications for Percutaneous Left Ventricular Assist Device (pvad) Support Mean SD (Range) Patients With Preexisting CHF Patients With Acute Ischemia Number Age (years) (48 87) (48 71) (61 87) Body surface area (m 2 ) ( ) ( ) ( ) EuroSCORE (6 17) (6 13) (6 17) Preoperative LVEF (%) (10 55) (10 25) (30 55) Evolving myocardial infarction 3 of 11 0 of 7 (0%) 3 of 4 (75%) Redo surgery 3 of 11 (27.3%) 2 of 7 (28.6%) 1 of 4 (25%) Emergency operation 6 of 11 (54.5%) 3 of 7 (48.9%) 3 of 4 (75%) IABP before LVAD 5 of 11 (45.5%) 1 of 7 (14.3%) 4 of 4 (100%) Surgery Isolated CABG 4 patients 0 of 7 4 of 4 Emergency redo MVR 1 patient 1 of 7 0 of 4 Surgical ventricular remodeling 6 patients 6 of 7 0 of 4 Indication for pvad Failure to wean from CPB 9 of 11 (81.81%) 6 of 7 (85.7%) 3 of 4 (75.0%) Preoperative decompensation 1 of 11 (9.1%) 1 of 7 (14.3%) 0 of 4 (0%) Postoperative cardiac arrest 1 of 11 (9.1%) 0 of 7 (0%) 1 of 4 (25%) CABG coronary artery bypass graft surgery; CPB cardiopulmonary bypass; EuroSCORE European System for Cardiac Operative Risk Evaluation; IABP intra-aorticballoon pump; LVAD left ventricular assist device; LVEF left ventricular ejection fraction; MVR mitral valve replacement. heart failure occurred as decompensation of preexisting end-stage chronic heart failure. Four patients underwent coronary artery bypass graft surgery for coronary artery disease and had acute de novo heart failure due to perioperative coronary syndromes. Indications and Criteria for TandemHeart Insertion The main indication for TandemHeart insertion was failure to wean from CPB (9 patients). Other indications were preoperative acute decompensation of end-stage chronic heart failure (1 patient) and postcardiotomy refractory cardiac arrest (1 patient). High doses of at least two catecholamines including epinephrine were administered to all 11 patients before initiation of mechanical assistance. In 5 patients (all 4 patients with acute ischemia and 1 patient with chronic heart failure), the TandemHeart was inserted after IABP failed. In 6 patients with chronic heart failure, the TandemHeart was inserted without previous IABP. In these patients with chronically dilated and hypokinetic hearts, criteria for MCS were failure to wean from CPB on first attempt despite maximum inotropic support, and minimal intrinsic pumping activity and marked LV dilatation not only on CPB withdrawal but even with CPB flows less than 1.5 L/min. The patients baseline characteristics and indications for MCS are shown in Table 1. Cannulation Among the 7 patients with preexisting chronic heart failure, the device was inserted in 1 patient preoperatively with the standard percutaneous technique (Fig 1c) as reported by Thiele and colleagues [8]. Two outflow arterial cannulas 15F were used. In the remaining 6 patients with preexisting chronic heart failure, an open transeptal insertion technique was employed intraoperatively. On CPB, the right atrial cannulation was converted to direct bicaval cannulation. Through the opening of the right atrial appendage, a pursestring suture was placed to the fossa ovalis. The long transeptal inflow cannula was inserted percutaneously through the right femoral vein, advanced inside the right atrium, guided under direct vision into the left atrium through a stab wound to the fossa ovalis, and secured in place by the pursestring suture (Fig 1). Outflow was by percutaneous bilateral femoral artery cannulation with two 15F Medtronic biomedicus cannulas in 4 patients or unilateral with a single 17F cannula in 2 patients (Fig 2). Direct cannulation of the ascending aorta and the left atrium through the right superior pulmonary vein (Fig 3) was employed in all 4 patients with acute ischemia, owing to peripheral vascular disease (3 patients) or to urgent need for initiation of support in an arrested postcardiotomy patient. The sternum was closed in all patients, with the exception of 1 patient in whom only the skin was closed. Pump Set-Up and Patient Management The pump speed was initially set between 5,900 rpm and the maximum speed of 7,500 rpm aiming to a cardiac index greater than 2.2 L/min measured by thermodilution, a mean systolic arterial pressure greater than 70 mm Hg, and a mixed venous oxygen saturation greater than 70%. After weaning from CPB, heparin was partially reversed with protamine. Continuous heparin infusion through the pump incorporated in the TandemHeart
3 Ann Thorac Surg PITSIS ET AL 2007;84: FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 1995 Fig 1. Open transeptal technique for device insertion. (1a) The percutaneously inserted inflow cannula is guided to the right atrium. (1b) The inflow cannula has been inserted to the left atrium through a stab wound to the fossa ovalis. (1c) The end result of both pure percutaneous cannulation and the open transeptal technique is the same. system was started intraoperatively or early postoperatively to maintain an activated clotting time of 180 s to 200 s. In 3 of 4 patients with acute ischemia, IABP was maintained during support; in 1 patient with severe peripheral atherosclerosis, the balloon inserted through the ascending aorta was removed to facilitate insertion of the TandemHeart outflow cannula. In the 7 patients with decompensated chronic heart failure, IABP was not used during support, as the LV offloading provided by the device and pulsatility provided by residual LV function were adequate. Progressively decreasing doses of inotropes were administered during support, and weaning was generally attempted after the first 24 hours. When the patients were hemodynamically stable, without excessive inotropic and vasoactive drugs (such as epinephrine or norepinephrine) and with good vital organ function, weaning was considered. Preload, afterload, cardiac rhythm, and ventricular function were optimized. Low to moderate doses of mirlinone, dobutamine, or dopamine were administered during the weaning procedure, which lasted between 2 and 12 hours. The pump flow was gradually decreased as tolerated, to a flow of 0.5 L/min (for short Fig 2. A patient with percutaneous insertion of cannulas during support. Fig 3. Direct cannulation.
4 1996 PITSIS ET AL Ann Thorac Surg FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 2007;84: periods with activated clotting time 220 s). If under these settings the cardiac index remained above 2.2 L/min, without ventricular dilatation and with adequate ventricular contraction, weaning was decided. Weaning from the ventilator started during support in hemodynamically stable patients, and most patients were extubated shortly after device removal. Device Removal In the 7 patients with percutaneous inflow and outflow cannulas insertion, the device was removed by simple withdrawal of the cannulas, followed by manual compression to achieve hemostasis at the percutaneous insertion sites. When direct cannulation was employed the device was removed in theater. Definitions and Measurements Cardiac output during support is defined as the right ventricular output measured by thermodilution. Residual cardiac output is defined as the cardiac output during support minus the device flow measured by the device flowmeter. Residual cardiac output in the setting of partial support LVAD represents the LV output through the aortic valve, and it is attributed to residual intrinsic function of the assisted left ventricle. Residual cardiac output equals cardiac output (thermodilution) minus LVAD flow [11]. Hemodynamic measurements immediately before initiation of support are not available because most patients were on CPB (n 9) and 1 patient was in cardiac arrest. Hemodynamic and pump measurements obtained within the first 2 hours from initiation of support (or reinitiation of support in the patient with preoperative insertion) are defined as initial measurements. Measurements made at a mean of hours from initiation of support are defined as measurements during support. Comparisons of these measurements were performed with the paired t test. Results The mean initial pump flow, pump speed, cardiac output (thermodilution), cardiac index, and residual cardiac output are shown in Table 2. On comparison of initial hemodynamics and hemodynamics during support of the 9 patients who survived beyond the first 6 hours of support, there was a significantly decreased diastolic systemic arterial pressure during support (p 0.002), reflecting increased pulsatility due to LV contribution to cardiac output, suggesting less severe ventricular compromise in those patients (Table 3). The mean durations of support, mechanical ventilation, intensive care unit stay, and postoperative hospital stay are shown in Table 4. Prolonged mechanical ventilation is attributed mainly to persisting or recurrent heart failure. Eight of 11 patients (72.72%) were weaned from the device. Six of 11 patients survived to discharge (54.54% of treated patients, 75% of weaned patients; Table 2). Among hospital survivors, 83.33% remained alive at 1 Table 2. Pump Measurements and Cardiac Output Direct Central Cannulation (Acute Ischemia) Percutaneous Cannulas Insertion (CHF) All Patients Mean SD, (Median, Range) Initial pump flow (L/min) (2.9, ) (2.5, ) (3.45, ) Initial pump speed (rpm) (6,500, 5,900 7,500) (6,400, 5,900 6,800) (7,500, 6,000 7,500) Initial total cardiac output (thermodilution) (L/min) (5.5, ) (5.6, ) (4.55, ) Initial total cardiac index (L/min/m 2 ) (2.9, ) (2.9, ) (2.41, ) Initial residual cardiac output (L/min) (2.8, ) (3, ) (0.9, ) CHF congestive heart failure.
5 Ann Thorac Surg PITSIS ET AL 2007;84: FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 1997 Table 3. Initial and During Support Hemodynamic Variables Means (mm Hg) Initial (n 9) During Support (n 9) Paired t Test Systolic arterial NS, p 0.49 BP mm Hg Diastolic p arterial BP mm Hg Mean systemic NS, p 0.78 BP mm Hg Systolic PAP NS, p 0.54 mm Hg Diastolic PAP NS, p 0.96 mm Hg Mean PAP mm NS, p 0.38 Hg PCWP mm Hg NS, p CVP mm Hg NS, p 0.61 BP blood pressure; CVP central venous pressure; NS not significant; PAP pulmonary artery pressure; PCWP pulmonary capillary wedge pressure. year and 66.66% remained alive at 4 years. Among survivors in 4 years, 1 patient was in New York Heart Association class I and 3 patients were in class II. All patients reported that they were independent in daily activities and considered the treatment worthwhile. Causes of Death All 3 patients who were not weaned from the device were taken to theater with evolving acute myocardial infarction and died of biventricular failure (Table 5). Their left ventricle never recovered; right-sided heart failure became evident (within 0.5 hour to 8 days after initiation of support) and was rapidly followed by death or multiple organ failure. Table 4. Weaning, Survival to Discharge, and Duration of Treatments Variable Value Able to be weaned 8 of 11 (72.72%) Survival to discharge 6 of 11 (54.54%) Survival to discharge 2 in 5 (40%) with previous IABP depending on IABP 4 in 6 (66.66%) with early support before LVAD support Duration of support (41, ) (hours) Duration of mechanical (7.5, ) ventilation (days) Duration of ICU stay (16.5, ) (days) Duration of hospital (26.5, ) stay (days) IABP intra-aortic balloon pump; ICU intensive care unit; L- VAD left ventricular assist device. Table 5. Causes of Death Patients not weaned Patients weaned Patient Characteristics Acute de novo heart failure due to preoperative acute myocardial infarction Decompensation of preexisting congestive heart failure Cause of Death Biventricular failure (n 3) Recurrence of left heart failure (n 2) Two patients with preexisting chronic heart failure were weaned but did not survive to discharge owing to recurrent heart failure. These patients died of low cardiac output syndrome refractory to inotropes and IABP or cardiorespiratory arrest on grounds of LV failure, unstable sternum, and severe respiratory infection. Adverse Events The most common adverse event during support was pericardial bleeding with similar incidence in central and femoral cannulation (Table 6). Five patients (45.45%) required reexploration for bleeding complications. In 1 patient, bleeding was attributed to a small vessel, and in the remaining patients, to bleeding diathesis. Diffuse bleeding requiring reexploration was significantly higher among patients receiving aspirin or clopidogrel preoperatively ( 2 test, p 0.033). Among the 7 patients with percutaneous cannulas insertion, 1 patient (14.28%) with unilateral arterial cannulation presented with late bleeding from the left common femoral artery due to cannula dislocation (resolved by device removal), and 1 patient with bilateral arterial cannulation required fasciotomy owing to compartment syndrome of the right leg. Documented respiratory infection presented during support in 3 patients but its relationship to the device per Table 6. Adverse Events During Percutaneous Ventricular Assist Device (pvad) Support Adverse Event Pericardial bleeding Respiratory tract infection Leg ischemia Femoral artery bleeding (minor dislocation of outflow cannula) Percentage of Patients 45.4% Reopening How Resolved 27.27% Intravenous antibiotic treatment 14.3% of patients Fasciotomy who underwent percutaneous insertion 14.3% of patients who underwent percutaneous insertion Removal of the pvad on the 5 th day of support
6 1998 PITSIS ET AL Ann Thorac Surg FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 2007;84: Table 7. Blood Product Transfusions se was not proven. All device cannula cultures after removal were negative. No thromboembolic or cerebrovascular events or device failures were noted. Excluding the patient in whom multiple organ failure followed the right-sided heart failure, there were no hepatic or renal complications based on clinical and laboratory data. Creatinine remained below 1.4 mg/dl, liver enzymes remained below triple the higher normal value. The mean lactate dehydrogenase was U/L. The platelet count increased after the third day of support in all 5 patients supported longer than 3 days. On transthoracic echocardiogram within 24 hours from device removal, among the 7 patients with transeptal inflow cannula insertion, no atrial septal defect was detected in 6 patients and a small, clinically insignificant atrial septal defect was detected in 1 patient. No atrial septal defect was detected on serial echocardiography. Blood product transfusions are shown in Table 7. Comment Mean / SD (Units) Range (Units) Median (Units) Packed red blood cells 5.8 / Fresh frozen plasma 6.72 / The generalized tendency toward minimally invasiveness has influenced the design and technology of VADs [12]. High mortality rates are reported early after weaning and device removal in postcardiotomy support [4, 5]. Avoiding surgical trauma during this critical period is desirable. TandemHeart is a versatile VAD allowing not only percutaneous insertion but also intraoperative open transeptal or direct cannulation. Although not purely percutaneous, the open transeptal technique involves percutaneous cannulas insertion and allows easy removal, avoiding surgical trauma. We performed percutaneous cannulas insertion to avoid resternotomy for device removal, prolonged mechanical ventilation, increased risk of infection, and hemodynamic and respiratory derangement. We performed direct central cannulation in patients with severe peripheral vascular disease or when support was urgently required for resuscitation in a patient with open sternum. No interference of the inflow cannula with the left ventricle with either cannulation technique had advantages since it was used in patients with acute myocardial infarction or after LV surgical remodeling. Although not maximal or directly comparable, in our patients, the TandemHeart flow with transthoracic cannulation was higher than that with percutaneous femoral cannulation. The flow with the transthoracically inserted TandemHeart (mean L/min, maximum 6.0 L/min) is comparable with that achieved by transthoracically inserted temporary VADs with other centrifugal or pulsatile pumps, microaxial flow pumps, and ECMO [4 6, 11, 13]. Although maximum flow of 4.5 L/min has been reported with the percutaneously inserted Tandem- Heart [14], in our patients, the maximum flow with percutaneous insertion was 3.1 L/min at a submaximal speed of 6,200 rpm (the mean flow being ). This flow is less than that achieved by ECMO and the Hemopump (Medtronic, Minneapolis, MN) inserted with open femoral cannulation and higher than that of the percutaneously inserted Hemopump [6, 13]. The incidence of pericardial bleeding is typical of that reported with commonly used extracorporeal centrifugal pumps and ECMO [4, 5], but it was higher that that reported for Impella (Cardiosystems AG, Aachen, Germany) [11], Hemopump [6], and temporary pulsatile VADs [4]. The incidence of bleeding was similar with percutaneous and direct cannulation, and it was higher among patients receiving antiplatelet treatment preoperatively. Delayed sternal closure could have been an option, but not without the disadvantages of restrainement to prevent cannulas dislodgment, sedation [5], prolonged mechanical ventilation, increased risk of infection, and reoperation for closure. Thromboelastography could guide the strategy of closure and blood product administration. Heparin withdrawal in the early postoperative hours could minimize the need of reexploration. The incidence of vascular complications is comparable with that reported with peripherally inserted ECMO [4, 15]. Anastomosis of a vascular graft to the common femoral artery to serve as a conduit for the arterial cannula could help in avoiding leg ischemia and cannula dislocation [4]. Despite advantages of easy device removal in percutaneous cannulation, owing to flow limitation and vascular complications, we would not recommend this approach in patients with no residual LV function, peripheral atherosclerosis, and small femoral arteries. Evaluation of results is closely related to the indications for MCS. Although the recommendation for IABP before LVAD support in acute heart failure is characterized as class I, level of evidence C [2], Baskett and colleagues [3] consider that there is class IIa, level of evidence C, for postoperative IABP in coronary artery bypass graft surgery patients, as some authors suggest [13]; or apply in practice [4, 5, 11] earlier initiation of mechanical support when the shock is less prevalent without delay after failure of IABP. The high incidence of complications after VAD implantation is directly related to prolonged attempted weaning periods from CPB [5]. Early MCS is considered justifiable if the risk for the patients is not increased by the adverse events related to the device itself [6]. Two randomized studies comparing TandemHeart support to IABP in patients with cardiogenic shock showed improved hemodynamic parameters with the TandemHeart and similar survival benefit [9, 16]. Intra-aortic balloon pumping to treat low cardiac output rather than ischemia has been associated with poorer prognosis [3]. In all patients with acute ischemia and in 1
7 Ann Thorac Surg PITSIS ET AL 2007;84: FEASIBILITY OF TEMPORARY PERCUTANEOUS LVAD 1999 patient with decompensated chronic heart failure, IABP preceded TandemHeart support. All these patients would have probably died as they were not responsive to all means of conventional treatment, but TandemHeart support led to survival of 2 of 5 patients (40%). In 6 patients with decompensated chronic heart failure, the TandemHeart was inserted without previous IABP. These patients would have probably died without some kind of mechanical support as they were not responsive to maximal conventional medical treatment. Although we can not produce evidence of superiority of Tandem- Heart in comparison with IABP (and perhaps IABP or another LVAD would have led to the same or better results), it was TandemHeart assistance that led to survival of 4 of 6 patients (66.6%). Weaning and survival to discharge with the Tandem- Heart was comparable with that reported with generally accepted centrifugal pumps, ECMO, pulsatile temporary VADs, and microaxial flow pumps in similar settings. Hospital discharge rates reported for patients receiving VADs postcardiotomy range between 20% and 60%, higher survival being observed when temporary VADs are used for bridging procedures [1, 4 6, 11, 13, 15, 17 19]. All patients who died on support had preoperative acute myocardial infarction and died of biventricular failure. The extent of myocardial injury has been underestimated in these patients who might have benefited by biventricular support or ECMO. Withdrawal of the inflow cannula to the right atrium and incorporation of an oxygenator to the circuit would allow switch to ECMO. Nevertheless, given that extensive myocardial damage is present in the majority of patients not surviving after postcardiotomy MCS, it has been considered unlikely that a specific VAD or mode of support could improve outcome [15]. In failure of cardiac recovery, early conversion to long term support could offer a life-saving alternative [15]. Mehta and Pae [14] recently reported conversion of the TandemHeart to long-term support. The cause of death in patients weaned from the device was recurrence of chronic left-sided heart failure. In these patients, heart failure surgery combined with early initiation of support to allow recovery from the operative insult yielded good results (100% weaning, 71.4% survival). Longer support to allow myocardial remodeling [20] could improve survival. In conclusion, versatility of cannulation, minimal invasiveness, and low cost are advantages of the Tandem- Heart. Rapid conversions to CPB with adequate flows and to long-term support have been recently shown. The adverse events during support were typical of those reported with other devices in similar settings. Device application yielded high cumulative weaning rate and satisfactory early and midterm survival. Percutaneous cannulation requires careful patient selection and biventricular failure necessitates urgent biventricular or ECMO support. We speculate that when poor outcome is anticipated, as in cases of extensive acute ischemic injury or persisting chronic heart failure, early implementation of a strategy to long-term support might improve outcomes. The authors thank Dr Emmanuel Psaltis for designing the Figures. References 1. Kirklin/Barratt-Boyes cardiac surgery. 3rd ed. Edinburgh: Churchill Livingston, 2003: Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005;26: Baskett RJF, Ghali WA, Maitland A, Hirsch GM. The intraaortic balloon pump in cardiac surgery. Ann Thorac Surg 2002;74: Moazami N, McCarthy PM. Temporary circulatory support. In: Cohn LH, Edmunds LH Jr, eds. Cardiac surgery in the adult. New York: McGraw-Hill, 2003: Noon GP, Lafuente JA, Irwin S. Acute and temporary ventricular support with biomedicus centrifugal pump. Ann Thorac Surg 1999;68: Meyns B, Sergeant P, Wouters P, et al. Mechanical support with microaxial blood pumps for postcardiotomy left ventricular failure: can outcome be predicted? J Thorac Cardiovasc Surg. 2000;120: Pitsis A, Dardas P, Mezilis P, Nikoloudakis N, Filippatos G, Burkhoff D. Temporary assist device for postcardiotomy heart failure. Ann Thorac Surg 2004;77: Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001;104: Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26: Edmunds LH Jr, Herrmann HC, DiSesa VJ, Ratcliffe MB, Bavaria JE, McCarthy DM. Left ventricular assist without thoracotomy: clinical experience with the Dennis method. Ann Thorac Surg 1994;57: Siegenthaler MP, Brehm K, Strecker T, et al. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004;127: Pitsis AA, Anagnostopoulos CE. Acute heart failure: is there a role for surgery? Heart Fail Rev 2007;12: Dreyfus GD. Hemopump 31, the sternotomy Hemopump: clinical experience. Ann Thorac Surg 1996;61: Mehta S, Pae W. Conversion of the Tandemheart percutaneous ventricular assist device to long-term support. Interact Cardiovasc Thorac Surg 2006;5: Smedira NG, Blackstone EH. Postcardiotomy mechanical support: risk factors and outcomes. Ann Thorac Surg 2001; 71(Suppl): Burkhoff D, Cohen H, Brunckhorst C, O Neill WW, and the Tandemheart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the Tandem- Heart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152:469.e Stevenson LW, Kormos RL, Bourge RC, et al. Mechanical cardiac support 2000: current applications and future trial design. J Am Coll Cardiol 2001;37: Joyce LD, Kiser JC, Eales F, et al. Experience with generally accepted centrifugal pumps: personal and collective experience. Ann Thorac Surg 1996;61: Körfer R, El-Banayosy A, Arusoglu L, et al. Temporary pulsatile ventricular assist devices and biventricular assist devices. Ann Thorac Surg 1999;68: Pitsis AA, Visouli AN, Vassilikos V, et al. First human implantation of a new rotary blood pump: design of the clinical feasibility study. Hellenic J Cardiol 2006;47:
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationEcho assessment of patients with an ECMO device
Echo assessment of patients with an ECMO device Evangelos Leontiadis Cardiologist 1st Cardiology Dept. Onassis Cardiac Surgery Center Athens, Greece Gibbon HLM 1953 Goldstein DJ et al, NEJM 1998; 339:1522
More informationECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan
ECMO as a bridge to durable LVAD therapy Jonathan Haft, MD Department of Cardiac Surgery University of Michigan Systolic Heart Failure Prevalence 4.8 million U.S. 287,000 deaths per year $39 billion spent
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationPlanned, Short-Term RVAD During Durable LVAD Implant: Indications and Management
Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management Yoshifumi Naka, MD, PhD Columbia University Medical Center New York, NY Disclosure Abbott/St. Jude Med./Thoratec Consultant
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationCath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationThe Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
More informationWhich mechanical assistance for cardiogenic shock?
Which mechanical assistance for cardiogenic shock? Alain Combes, MD, PhD, Hôpital Pitié-Salpêtrière, AP-HP Inserm UMRS 1166, ican, Institute of Cardiometabolism and Nutrition Pierre et Marie Curie Sorbonne
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationRhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale
A Randomized Clinical Study To Compare The Intra-Aortic Balloon Pump To A Percutaneous Left Atrial-To-Femoral Arterial Bypass Device For Treatment Of Cardiogenic Shock Following Acute Myocardial Infarction.
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationInitial Experience With Miniature Axial Flow Ventricular Assist Devices for Postcardiotomy Heart Failure
CARDIOVASCULAR Initial Experience With Miniature Axial Flow Ventricular Assist Devices for Postcardiotomy Heart Failure Michael J. Jurmann, MD, Henryk Siniawski, MD, Michael Erb, MD, Thorsten Drews, MD,
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationRight Heart Failure in LVAD patients: Prevention and Management.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania Right Heart Failure in LVAD patients: Prevention and
More informationTo ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW
To ECMO Or Not To ECMO Challenges of venous arterial ECMO Dr Emily Granger St Vincent s Hospital Darlinghurst NSW The Start: 1972 St Vincent s Hospital The Turning Point ECMO program restarted in 2004
More informationMechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017
Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Pascal Vranckx MD, PhD. Medical director Cardiac Critical Care Services Hartcentrum Hasselt Belgium Disclosure
More informationVentricular Assisting Devices in the Cathlab. Unrestricted
Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationHemodynamic Monitoring and Circulatory Assist Devices
Hemodynamic Monitoring and Circulatory Assist Devices Speaker: Jana Ogden Learning Unit 2: Hemodynamic Monitoring and Circulatory Assist Devices Hemodynamic monitoring refers to the measurement of pressure,
More informationCENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA
CENTRAL ECMO WHEN AND HOW? RANJIT JOHN, MD UNIVERSITY OF MINESOTA Background How to do Case reports When to do Managing complications Post operative management strategies CASE PRESENTATION 46 year old
More informationAcute Mechanical Circulatory Support Right Ventricular Support Devices
Acute Mechanical Circulatory Support Right Ventricular Support Devices Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele
More informationIschemic Ventricular Septal Rupture
Ischemic Ventricular Septal Rupture Optimal Management Strategies Juan P. Umaña, M.D. Chief Medical Officer FCI Institute of Cardiology Disclosures Abbott Mitraclip Royalties Johnson & Johnson Proctor
More informationLV Distension and ECLS Lungs
LV Distension and ECLS Lungs Kevin W. Hatton, MD, FCCM Interim Vice-Chair for Anesthesiology Research Division Chief, Anesthesiology Critical Care Medicine Program Director, Anesthesiology Critical Care
More informationInitial experience with Imacor htee-guided management of patients following transplant and mechanical circulatory support.
Thomas Jefferson University Jefferson Digital Commons Department of Cancer Biology Faculty Papers Department of Cancer Biology Fall 11-1-2012 Initial experience with Imacor htee-guided management of patients
More informationHardware in the Chest - From VADs to Valves
Hardware in the Chest - From VADs to Valves Cristina Fuss, MD Purpose Recognize the device Indication and function Cristina Fuss, MD Department of Diagnostic Radiology FROM VADS TO VALVES Implanting technique
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationAATS/Cardiothoracic Critical Care Symposium
AATS/Cardiothoracic Critical Care Symposium Balancing Pharmacologic and Mechanical Support Robert L Kormos MD, FACS, FRCS(C), FAHA I have no disclosures and will not discuss off label use of drugs or devices
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Percutaneous Coronary Intervention https://www.youtube.com/watch?v=bssqnhylvma Types of PCI Procedures Balloon Angioplasty Rotational Atherectomy Coronary Stent Balloon Inflation Rotational Atherectomy
More informationCASE PRESENTATION Ravi Dhanisetty, M.D. SUNY Downstate 23 July 2009 CASE PRESENTATION xx yr old female with chest pain for 3 days. Initially taken to outside hospital 3 days history of chest pain, shortness
More informationCARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)
CARDIOGENIC SHOCK Antonio Pesenti Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI) Primary myocardial dysfunction resulting in the inability of the heart to mantain an
More informationIntra-operative Echocardiography: When to Go Back on Pump
Intra-operative Echocardiography: When to Go Back on Pump GREGORIO G. ROGELIO, MD., F.P.C.C. OUTLINE A. Indications for Intraoperative Echocardiography B. Role of Intraoperative Echocardiography C. Criteria
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationDisclosures. Objectives 10/11/17. Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock. I have no disclosures to report
Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock Christopher K. Gordon MSN, ACNP-BC Disclosures I have no disclosures to report 1. Pathophysiology 2. Epidemiology 3. Assessment
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City
More informationLow cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ
Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output/cardiogenic Shock State of end-organ hypoperfusion due to cardiac failure.
More informationComplications of Acute Myocardial Infarction
Acute Myocardial Infarction Complications of Acute Myocardial Infarction Diagnosis and Treatment JMAJ 45(4): 149 154, 2002 Hiroshi NONOGI Director, Division of Cardiology and Emergency Medicine, National
More informationI tion (OCT) has been related to advances in myocardial
The Pierce-Donachy Ventricular Assist Device as a Bridge to Cardiac Transplantation Laman A. Gray, Jr, MD, Brian L. Ganzel, MD, Constantine Mavroudis, MD, and A. David Slater, MD Division of Thoracic and
More informationInnovative ECMO Configurations in Adults
Innovative ECMO Configurations in Adults Practice at a Single Center with Platinum Level ELSO Award for Excellence in Life Support Monika Tukacs, BSN, RN, CCRN Columbia University Irving Medical Center,
More informationNumber: Policy *Please see amendment for Pennsylvania Medicaid at the end. Last Review 03/23/2017 Effective: 03/25/2003 Next Review: 07/26/2018
1 of 47 Number: 0654 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers a Food and Drug Administration (FDA) approved ventricular assist device (VAD)* medically
More informationMechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography
Mechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography David Langholz, M.D., F.A.C.C. Co-Director Cardiovascular Imaging Fredrick Meijer Heart and Vascular Institute Spectrum
More informationCase scenario V AV ECMO. Dr Pranay Oza
Case scenario V AV ECMO Dr Pranay Oza Case Summary 53 y/m, k/c/o MVP with myxomatous mitral valve with severe Mitral regurgitation underwent Mitral valve replacement with mini thoracotomy Pump time nearly
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationStrategies for the High Risk Redo in CHD
Strategies for the High Risk Redo in CHD Joseph A. Dearani, MD AATS, Minneapolis 2013 Strategies for the High Risk Redo in CHD Joseph A. Dearani, MD AATS, Minneapolis 2013 No Disclosures 2011 MFMER slide-3
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationCase - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
More informationCardiogenic Shock Protocol
Cardiogenic Shock Protocol Impella Devices Best Practices in AMI Cardiogenic Shock Identify 1-3 SBP < 90 mmhg or on inotropes /pressors Cold, clammy, tachycardia Lactate elevated > 2 mmoi /L Stabilize
More informationEarly and Intermediate Results of Rescue Extracorporeal Membrane Oxygenation in Adult Cardiogenic Shock
Early and Intermediate Results of Rescue Extracorporeal Membrane Oxygenation in Adult Cardiogenic Shock Jiangang Wang, MD, Jie Han, MD, Yixin Jia, MD, Wen Zeng, MD, Jiahai Shi, MD, Xiaotong Hou, MD, and
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationMinimally invasive left ventricular assist device placement
Original Article on Cardiac Surgery Minimally invasive left ventricular assist device placement Allen Cheng Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, USA
More informationUnderstanding the Cardiopulmonary Bypass Machine and Its Tubing
Understanding the Cardiopulmonary Bypass Machine and Its Tubing Robert S. Leckie, MD Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center ABL 1/09 Reservoir Bucket This is a cartoon of
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationEvaluation of the Right Ventricle in Candidates for Right Ventricular Assist Device Implantation.
Evaluation of the Right Ventricle in Candidates for Right Ventricular Assist Device Implantation. Evaluation of RVAD Function. Ioannis A Paraskevaidis Attikon University Hospital Historical Perspective
More informationFrom Recovery to Transplant: One Patient's Journey
From Recovery to Transplant: One Patient's Journey Tonya Elliott, RN, MSN Assist Device and Thoracic Transplant Coordinator Inova Transplant Center at Inova Fairfax Hospital Falls Church, VA Introduction
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationName of Policy: Ventricular Assist Devices and Total Artificial Hearts
Name of Policy: Ventricular Assist Devices and Total Artificial Hearts Policy #: 033 Latest Review Date: February 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationRetrospective Study Of Redo Cardiac Surgery In A Single Centre. R Karthekeyan, K Selvaraju, L Ramanathan, M Rakesh, S Rao, M Vakamudi, K Balakrishnan
ISPUB.COM The Internet Journal of Anesthesiology Volume 12 Number 2 Retrospective Study Of Redo Cardiac Surgery In A Single Centre R Karthekeyan, K Selvaraju, L Ramanathan, M Rakesh, S Rao, M Vakamudi,
More informationGiving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
More informationVENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS
Status Active Medical and Behavioral Health Policy Section: Surgery Policy Number: IV-86 Effective Date: 03/26/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationHeart-lung transplantation: adult indications and outcomes
Brief Report Heart-lung transplantation: adult indications and outcomes Yoshiya Toyoda, Yasuhiro Toyoda 2 Temple University, USA; 2 University of Pittsburgh, USA Correspondence to: Yoshiya Toyoda, MD,
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationECMO and VAD implantation
1 Udine ECMO Workshop ECMO and VAD implantation Prof. Tomaso Bottio Division of Cardiac Surgery (Director Prof. Gino gerosa) ECMO Extracorporeal membrane oxygena1on (ECMO) is a rescue therapy to support
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationCardiogenic Shock in Acute MI
Cardiogenic Shock in Acute MI Mark Sheldon, MD UNMH Interventional Cardiology Objectives Overview Treatment Definition Shock profiles Causes Medical Mechanical Illustrative case Questions? Revascularization
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationRay Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
More informationPUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR
PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR Dr Susanna Price MD PhD MRCP ESICM FFICM FESC Consultant Cardiologist & Intensivist Royal Brompton & Harefield NHS Foundation Trust DECLARATIONS Educational
More informationMechanical ventricular support is infrequently required for recipients
Cardiopulmonary Support and Physiology Petrofski et al BVS5000 support after cardiac transplantation Jason A. Petrofski, MD a Vijay S. Patel, MD a Stuart D. Russell, MD b Carmelo A. Milano, MD a Objective:
More informationAcute peri-operative. Alexandre Mebazaa, Hôpital Lariboisière, Université Paris 7 U942 Inserm
Acute peri-operative left heart failure Alexandre Mebazaa, Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts for this lecture Acute peri-operative
More informationEmergency Intraoperative Echocardiography
Emergency Intraoperative Echocardiography Justiaan Swanevelder Department of Anaesthesia, Glenfield Hospital University Hospitals of Leicester NHS Trust, UK Carl Gustav Jung (1875-1961) Your vision will
More informationInitial Experience With Single Cannulation for Venovenous Extracorporeal Oxygenation in Adults
Initial Experience With Single Cannulation for Venovenous Extracorporeal Oxygenation in Adults Christian A. Bermudez, MD, Rodolfo V. Rocha, MD, Penny L. Sappington, MD, Yoshiya Toyoda, MD, PhD, Holt N.
More informationSurgical Options for Temporary MCS
Surgical Options for Temporary MCS Michael A. Acker, MD Julian Johnson Professor of Surgery Chief of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania Health System
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More information